Physician
Access Medical Affordable Family Healthcare, LLC
Access Medical Affordable Family Healthcare, LLC was paid $2.00M by Medicaid between Jan 2018 and Mar 2024, across 43 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 39% of everything it billed.
33Billing provider infoACCESS MEDICAL AFFORDABLE FAMILY HEALTHCARE, LLC
TULSA, OK 74145
TULSA, OK 74145
33aNPI1588995534assigned 01/14/2010
33bProvider typeFamily Medicine Physician
28Total paid$2.00M
24GClaims49,213
24DCodes billed43
24AFirst – last monthJan 2018 – Mar 2024
Compared with peers
Next to other Family Medicine Physician providers in Oklahoma
Rank by total paid#24 of 351
Median peer was paid$153K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,245 | $309K | |
| 2019 | 6,824 | $308K | |
| 2020 | 6,439 | $248K | |
| 2021 | 8,071 | $299K | |
| 2022 | 10,151 | $424K | |
| 2023 | 9,428 | $362K | |
| 2024incomplete | 1,055 | $55K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 39% | 8,221 | 7,616 | $790K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 37% | 11,177 | 10,353 | $733K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.1% | 677 | 677 | $62K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.5% | 348 | 348 | $50K |
| 99406 | 2.2% | 3,397 | 3,099 | $45K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.2% | 2,473 | 2,347 | $44K |
| 96127 | 1.8% | 9,124 | 8,180 | $36K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.3% | 286 | 286 | $26K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.3% | 250 | 250 | $25K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.1% | 1,313 | 1,307 | $23K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.1% | 265 | 263 | $22K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,198 | 2,093 | $19K |
31 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 454 | $15K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 746 | $15K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 330 | $15K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,539 | $14K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 306 | $10K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 99 | $10K |
| 99385 | <1% | 87 | $10K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 199 | $6K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 51 | $5K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 251 | $5K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 23 | $3K |
| 90686 | <1% | 434 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 135 | $2K |
| 99384 | <1% | 15 | $2K | |
| 99386 | <1% | 13 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 69 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 112 | $2K |
| 99173 | <1% | 579 | $1K | |
| 99383 | <1% | 12 | $1K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 14 | $1K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 13 | $836.27 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 59 | $622.40 |
| 99490 | Ccm add 20min | <1% | 163 | $562.51 |
| 81025 | <1% | 73 | $559.93 | |
| 90756 | <1% | 22 | $417.46 | |
| 99407 | <1% | 16 | $378.77 | |
| 90674 | <1% | 13 | $151.91 | |
| 96160 | <1% | 1,548 | $151.37 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 71 | $34.31 |
| 90651 | 0% | 26 | $0.00 | |
| 90734 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFERRELL, CANNEN (ADMINISTRATION)
| Provider | Location | Paid |
|---|---|---|
| Access Pain Solutions | Tulsa, OK | $13.10M |
| Access Solutions Medical Group II | Okmulgee, OK | $1.07M |
| Dermatology & Allergy Solutions LLC | Broken Arrow, OK | $26K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.